One CRISPR treatment cut “bad” cholesterol in half for a full year

In a significant development for cardiovascular health, an experimental CRISPR gene-editing therapy has demonstrated remarkable efficacy in reducing "bad" cholesterol levels. A single dose of this innovative treatment was administered to patients suffering from difficult-to-treat lipid disorders, yielding substantial and sustained reductions in both LDL cholesterol and triglycerides.

The clinical findings indicate that the therapy cut these key lipid markers by approximately half. Importantly, these beneficial reductions were not fleeting; they remained present a full year after the initial single dose. This sustained effect is a crucial aspect, suggesting a long-term impact from a one-time intervention.

Further analysis revealed precise figures for the highest dose administered. Patients receiving this dose experienced a 52.5% decrease in LDL cholesterol, often referred to as "bad" cholesterol due to its role in arterial plaque buildup. Concurrently, triglyceride levels also saw a significant drop of 47.8%. These results highlight the potential of CRISPR technology to offer a powerful new therapeutic avenue for individuals struggling to manage their lipid profiles through conventional treatments. The persistent reduction observed over a year underscores the therapy's promise as a durable solution for a challenging medical condition.

What to watch: Further trials will be critical to confirm safety, long-term efficacy, and regulatory approval.

Editor's note: The article accurately reports the specific clinical trial percentages and outcomes mentioned in the source summary.

This article is AI-generated and fact-gated. Original reporting: ScienceDaily